Cellmid Limited (ASX: CDY) is an Australian life sciences company listed on the ASX and dedicated to creating shareholder value through commercialisation of its intellectual property relating to novel targets midkine and FGF5.

The Company’s Advangen subsidiary is focused on rapidly scaling the multi-channel distribution of flagship, clinically proven évolis® product ranges in Asia, USA, Europe and Australia.

Lyramid, the Company’s wholly owned subsidiary, is developing the extensive intellectual property assets around midkine with the view to partner for clinical development. Lyramid’s therapeutic interests include inflammation, fibrosis, osteoporosis, chronic kidney disease, and heart failure.

Shop évolis®

Subscribe to our newsletter